@prefix this: <http://purl.org/np/RA2RqUnRCJvJU4BCc_aaDIS59BFJ2GM1MueMUZXBMvbG0> .
@prefix sub: <http://purl.org/np/RA2RqUnRCJvJU4BCc_aaDIS59BFJ2GM1MueMUZXBMvbG0#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0008114> a biolink:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0008114>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/DRUGBANK:DB00363>;
    a rdf:Statement;
    rdfs:label "Clozapine is not recommended for OCD due to poor evidence of efficacy [170]. In addition, several case reports and clinical studies support the association of clozapine with worsening or onset of obsessive-compulsive symptoms in patients with a psychotic disorder [171-176]. At least 20% of individuals treated with clozapine (and other antiserotonergic antipsychotics) would experience worsening or emergence of obsessive-compulsive symptoms [177], which are dose-related [178] and generally reversible upon discontinuation of clozapine treatment and switch to a different antipsychotic [179]";
    biolink:has_population_context sub:context;
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:publications <https://pubmed.ncbi.nlm.nih.gov/30101713>;
    biolink:relation <https://w3id.org/um/neurodkg/OffLabelIndication> .
  
  sub:context a biolink:Cohort;
    rdfs:label "adults" .
  
  <https://identifiers.org/DRUGBANK:DB00363> a biolink:Drug .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-08-25T14:52:29.045065"^^xsd:dateTime .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
    npx:hasSignature "GsbY5Rbf6Gbvaiit2lQi84DcwIpIcxQg1AFco8HJT0BKmN2VqnPquPkYM9KgdePNBhe65iEH+k+zJjAeLnsqZdoNsCl55SrU56jJTiDFSld3kMbWYkyXoMrWYlLsyGSo8z9O9/MXAvNbpoRLYIsp+6P1gs2DqdM5mr/Q0Wf4ve8=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-08-25T14:52:29.045065"^^xsd:dateTime;
    prov:wasAttributedTo <https://orcid.org/0000-0002-7641-6446>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}